CHU de Rouen
Rouen, 76031, France
NCT Number: NCT02029898
One of the problems during general anesthesia (GA) for caesarean section is the place of opioid agents. Indeed, the literature does not provide so far a clear answer regarding the use of opioids prior to extraction of the newborn. Indeed, if the opioid administration at induction is beneficial for the mother (better control of autonomic responses to noxious stimuli), the impact on the newborn can be unfavorable in terms of adaptation to extrauterine life . This is especially true if the birth takes place in a context of prematurity and / or acute fetal distress.
The pharmacokinetics of remifentanil make it the only opioid which is consistent with a rapid sequence induction. Its short period of action avoids the manual ventilation of patients before intubation, while providing a peak of action concomitant to the nociceptive stimulation. Patients at high risk of aspiration, including pregnant women, may benefit from this type of morphine at induction. In addition, the fact that remifentanil seems to be associated with relative fetal safety in obstetrical or neonatal context legitimized the development of protocols to study maternal-fetal consequences of the use of remifentanil at induction of AG for emergency caesarean section.
While cesarean section under general anesthesia mainly concern premature newborns in France, no work has focused on the use of remifentanil for caesarean section in a context of preterm without preeclampsia.
The main hypothesis of this study is to evaluate the safety of the use of remifentanil in terms of adaptation to extrauterine life in children born prematurely by caesarean section under general anesthesia outside the context of preeclampsia.
To do this, we will compare two groups of children, one consisting of children born by cesarean section under general anesthesia with maternal remifentanil infusion, the other made up of children born by cesarean section under general anesthesia without maternal infusion of remifentanil. This study is prospective, single-center, randomized, double-blinded.
The primary endpoint is formed by the value of the Apgar score less than 7 at 5 minutes, calculated in the delivery room by the team supporting the child (midwives and pediatricians).
The secondary endpoints are formed by maternal hemodynamic parameters (SBP, DBP, MAP, HR), the rate of complications during induction (difficult intubation, aspiration), the onset of respiratory distress requiring ventilation mask in the newborn, the rate of intubation in neonates, and the rate of use of adjuvant anesthetic agents.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 1 / Phase 2
Rouen, 76031, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
of the mother:
Inclusion criteria
of the child:
Parents informed and written consent signed by the father and mother for the participation in this research by the child (unless a parent no longer has parental authority)
Exclusion criteria
Non-inclusion criteria of the mother:
Non-inclusion criteria of the child:
Fetal pathology diagnosed in the prenatal period involving the prognosis of the child
Time frame: 5 minutes afer birth
Apgar Score value below 7 after 5 minutes calculated in the delivery room by the team supporting the child (midwives or pediatric)
Time frame: intraoperative
Time frame: intraoperative
Time frame: intraoperative
Time frame: intraoperative
Time frame: intraoperative
Time frame: intraoperative
University Hospital, Rouen
Other
Adaptation to Neonatal Life After an Anesthetic Protocol Using Remifentanil for General Anesthesia for Caesarean Section in a Context of Prematurity - REAGI Protocol
Acronym: REAGI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07327320
Anesthesia, Cardiovascular Diseases
Ho Chi Minh City, Ho Chi Minh, Vietnam
View Trial DetailsNCT03006042
Adverse Effect, Anesthesia
View Trial DetailsNCT06524713
Anesthesia, Cesarean Section
Kocaeli, Turkey (Türkiye)
View Trial DetailsNCT07720440
Agnosia, Behavior
Istanbul, Sultangazi, Turkey (Türkiye)
View Trial Details